drugset / Trial / NCT00005106

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00005106

Phase 4 Completed 230 enrolled Glaxo Wellcome
Parallel-groupTreatment

Summary

The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.

Timeline

Start
1999-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg
Subject Nelfinavir Other / unclassified 1250 mg
Subject Stavudine Other / unclassified 40 mg
Subject Zidovudine Small molecule 300 mg
Background Lamivudine Other / unclassified 150 mg